NCT02892123 2024-11-27Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersJazz PharmaceuticalsPhase 1 Completed279 enrolled
NCT03043313 2024-11-26Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerSeagen Inc.Phase 2 Completed117 enrolled 21 charts 1 FDA